Inovio Pharmaceuticals Inc (NASDAQ:INO)
| 12.00 Delayed Data As of 3:59pm ET |  +0.32 / +2.74%Today’s Change | 3.60 Today|||52-Week Range 33.79 | +35.59% Year-to-Date |
Latest INO News | Press Releases
| Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy? Feb 22 / Zacks.com - Paid Partner Content | Better Coronavirus Stock: Inovio Pharmaceuticals vs. Vaxart Feb 15 / MotleyFool.com - Paid Partner Content |
| Inovio (INO) to Report Q4 Earnings: What's in the Cards? Feb 22 / Zacks.com - Paid Partner Content | Why Inovio Pharmaceuticals Stock Is Soaring Today Feb 12 / MotleyFool.com - Paid Partner Content |
| Are Short-Sellers Right About Inovio? Feb 21 / MotleyFool.com - Paid Partner Content | Could Inovio Pharmaceuticals Be a Millionaire-Maker Stock? Feb 12 / MotleyFool.com - Paid Partner Content |
| Inovio Pharmaceuticals (INO) Dips More Than Broader Markets: What You Should Know Feb 19 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 11.68 |
| Today’s open | 11.80 |
| Day’s range | 11.50 - 12.17 |
| Volume | 373,037 |
| Average volume (3 months) | 13,776,193 |
| Market cap | $2.8B |
Data as of 3:59pm ET, 02/24/2021
Growth & Valuation
| Earnings growth (last year) | -15.39% |
| Earnings growth (this year) | +4.50% |
| Earnings growth (next 5 years) | 0.00% |
| Revenue growth (last year) | -86.51% |
| P/E ratio | NM |
| Price/Sales | 79.23 |
| Price/Book | 408.68 |
Competitors
Data as of 3:59pm ET, 02/24/2021
Financials
| Next reporting date | March 2, 2021 |
| EPS forecast (this quarter) | -$0.22 |
| Annual revenue (last year) | $4.1M |
| Annual profit (last year) | -$119.4M |
| Net profit margin | -2,902.75% |
Profile
Sector Health Technology |
Industry Medical Specialties |
No executives to display |
Corporate headquarters Plymouth Meeting, Pennsylvania |
Forecasts
